Soleno (SLNO) Q2 Revenue Jumps 30%

Soleno Therapeutics (NASDAQ:SLNO), a biotech company focused on rare disease treatments, posted its inaugural commercial revenue following the U.S. launch of VYKAT XR for Prader-Willi syndrome (PWS). In its earnings release on August 6, 2025, the company reported GAAP revenue of $32.7 million. This result was well ahead of analyst predictions, which had expected $25.14 million in GAAP revenue. Earnings per share (EPS, GAAP) improved to $(0.09), a beat of $0.36 per share (GAAP) compared to consensus. The quarter marks a major milestone as Soleno transitions from developing therapies to commercial sales, showing promising early demand but also highlighting rising costs associated with launching a first-in-class treatment.

Source: Analyst estimates for the quarter provided by FactSet.

Soleno Therapeutics develops therapies for rare diseases, with a primary focus on Prader-Willi syndrome, a genetic disorder that causes chronic hunger and severe obesity due to hyperphagia. VYKAT XR, its lead product, is a once-daily extended-release tablet designed to manage hyperphagia in people living with PWS.

Continue reading

Source Fool.com